Health Care • Biotechnology: Pharmaceutical Preparations
$0.83 ▼ -0.09
(-9.79%)
MKT CAP: $5.5M • VOL: 20.3K
52W L $1 52W H $3
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
BGMS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $43.0K | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.4M | -$12.0M | -$25.5M |
| Operating Margin % | — | -80.0% | — |
| Net Income (GAAP) | -$3.0M | -$11.2M | $22.6M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$4.8M | -$8.0M | -$16.1M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$4.8M | -$8.0M | -$16.1M |
| FCF Margin % | — | -80.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $3.5M | $3.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.8M | -$2.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BGMS.